Discovery and Development of Targeted Anticancer Nanomedicines
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1694
Special Issue Editor
Interests: nanozymes; extracellular vesicles; drug delivery system; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is one of the most challenging diseases to treat and a global leading cause of death, and its related mortality is expected to rise to 13.1 million by 2030. Chemotherapy and radiation with non-selectivity limitations have led to the discovery and development of novel strategies for safe and effective cancer therapy treatment. Nanomedicine, as a potential area for cancer therapy, is used primarily as a source of nanocarriers or delivery agents for anticancer drugs due to its modulated biodistribution, its ability to protect medicines against degradation, and its ability to induce target-site accumulation of chemotherapeutic drugs, thereby reducing their toxicity. Furthermore, nanocarriers loaded with chemotherapeutic agents also overcome biological barriers such as renal and hepatic clearance, thus improving therapeutic efficacy. In addition, biomimetic nanomedicines coated with cell membrane can be used for targeted anticancer drug delivery thanks to their natural ability to target tumor cells.
In this Special Issue, we aim to highlight the importance of advanced nanomaterials and functional materials for targeted cancer therapy. We cordially invite authors to contribute original research articles, reviews, or shorter perspective articles on all aspects of the theme: “Discovery and Development of Targeted Anticancer Nanomedicines”. We especially welcome expert articles describing the potential of various nanomaterials for application in targeted cancer therapy, including their current state and clinical prospects.
Prof. Dr. Mingzhen Zhang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- drug delivery systems
- nanomaterials
- nanomedicine
- nanoparticle
- nanotechnology
- targeted therapy
